We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
For more than a month, PCSK9 partners Sanofi and Regeneron have been shopping some long-awaited outcomes data showing that their cholesterol drug Praluent can cut cardiovascular death risks.